ATS 2018 International Conference - Mobile

The Selective Prostacyclin Receptor Agonist ACT-333679 Attenuates and Reverses TGFb1-Induced Profibrotic Phenotype in Primary Human Lung Fibroblasts [Board No. P267]

Location: Board no. P267

Session Type: Thematic Poster Session

Tuesday

May

22

11:15 AM

1:00 PM

Speaker(s)/Author(s)

John Gatfield

PhD
Actelion Pharmaceuticals Ltd.

Rolf Studer

-
Actelion Pharmaceuticals Ltd.

Katarina Zmajkovicova

PhD
Actelion Pharmaceuticals Ltd.

Matthias Bollinger

-
Actelion Pharmaceuticals Ltd.

Berengere Renault

-
Actelion Pharmaceuticals Ltd.

Oliver Nayler

PhD
Actelion Pharmaceuticals Ltd.

Marie Schnoebelen

-
Actelion Pharmaceuticals Ltd.

Katalin Menyhart

-
Actelion Pharmaceuticals Ltd.

Yasmina Bauer

PhD
Actelion Pharmaceuticals Ltd.

View Abstract

The Selective Prostacyclin Receptor Agonist ACT-333679 Attenuates and Reverses TGFb1-Induced Profibrotic Phenotype in Primary Human Lung Fibroblasts

Parent Sessions

C72 - PULMONARY FIBROSIS: MECHANISMS AND MODELS...
05-22-2018 9:15 AM - 4:15 PM